Pulmatrix, Inc. (PULM) Investor Relations Documents

Pulmatrix, Inc. (PULM) investor relations documents from the company's IR site: 2 presentations, 8 press releases; latest deck 2024-03-04. Read in-app with summaries. First-party data.

Investor Presentation: Pulmatrix is a clinical-stage biopharmaceutical company leveraging its iSPERSE technology to develop respiratory and CNS therapeutics, led by lead candidate PUR3100.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-04-21Press releasePulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger
2026-03-26Press releasePulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan
2026-03-02Press releasePulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities
2025-12-18Press releasePulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives
2024-11-13Press releasePulmatrix and Cullgen Announce Proposed Merger
2024-05-29Press releasePulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation
2024-05-15Press releasePulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100
2024-03-04PresentationInvestor Presentation
2024-01-08Press releasePulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Part
2023-02-03Presentationhttps://ir.pulmatrix.com/download/PULM_Slides_DHE_KOL_Event_FINAL.pdf

PULM overview · PULM earnings · PULM financials · PULM KPIs · PULM ownership · PULM peers · PULM filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.